One of the most persistent challenges in vaccine clinical trials is generating precise, timely data across a large and often widely dispersed participant population. Reactogenicity events such as fever, injection site reactions, and fatigue typically emerge and resolve within 24 to 72 hours of dosing, a timeline that often outpaces paper diaries and scheduled follow-up calls.
At the same time, sponsors need to detect safety signals quickly across thousands of participants and manage data collection for trials that increasingly extend beyond traditional site visits. Continuous monitoring addresses each of these demands at once, generating objective, time-stamped data on reactogenicity, surfacing safety signals in near real time, and supporting decentralized data collection without adding burden to the participant.
This blog will cover:
The reactogenicity window is short by design, but that brevity is exactly what makes it hard to study well. A participant who develops a low-grade fever six hours after dosing and recovers by the next morning may never report it accurately if the only touchpoint is a diary entry filled in the following day or a phone call scheduled 48 hours out. Recall bias, inconsistent timing, and simple forgetfulness all work against data quality in a window this narrow. Sponsors need a method of observation that matches the actual pace of the reaction, not the pace of the trial's visit schedule.
Continuous monitoring improves oversight by generating data as the reaction unfolds rather than after the fact. Temperature, heart rate, and activity level can all be tracked passively, which means the trial captures the full reaction curve, onset, peak, and resolution, without depending on participant memory or manual reporting. This is particularly valuable for eCOA workflows, where sponsors are already working to reduce the burden of active data entry while improving the reliability of what gets recorded.
That same continuous data stream also strengthens trial safety and operational flexibility in ways that extend past reactogenicity alone. Real-time physiological data allows sponsors to flag anomalous patterns, such as unexpected cardiac irregularities or unusually prolonged fever, more quickly than a scheduled analysis point would allow. This matters most in large cohorts, where a slow-moving signal can affect thousands of participants before it becomes visible through conventional reporting.
Continuous monitoring also reduces the burden on participants directly. Fewer required site visits and less reliance on manual symptom logging make trials more accessible, which supports decentralized and hybrid designs where participants may be enrolled across a wide geographic area. For these designs to hold up to regulatory scrutiny, the underlying data still needs to meet EDC integration standards and support proper eConsent workflows, but the operational benefit for both sponsors and participants is substantial.
Vaccine trials will continue to demand fast, accurate safety data from large and often dispersed populations. Continuous monitoring meets that demand directly, capturing reactogenicity as it happens, strengthening safety signal detection, and making decentralized trial designs more operationally sound. For sponsors evaluating how to modernize vaccine trial monitoring, the technology is available now with RPM wearables.
Vivalink’s RPM devices and data infrastructure are built to support the pace and scale vaccine trials require, from continuous reactogenicity capture through EDC-ready data integration. Contact us to learn how our platform can support your next vaccine study.